Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: April 3, 2025
Reporting Period: Current (Event-based filing)
Principal Executive Office: Marseille, France
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a cover document for a press release (Exhibit 99.1) and does not contain embedded financial statements or quantitative data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document references a press release dated April 3, 2025, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the cover page, exhibit index, and signature block.
Investor Verification Checklist
- Review the full text of the Press Release dated April 3, 2025 (Exhibit 99.1) referenced in this filing to understand the specific event triggering the report.
- Verify if the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements, which are typical for this biopharmaceutical issuer.
- Check subsequent filings (e.g., Form 20-F or 8-K) for detailed financial impacts related to the event announced on April 3, 2025.